Prenatal screening for cystic fibrosis

Carolyn (Sue) Richards, James E. Haddow

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

This article focuses on essential components related to prenatal screening for cystic fibrosis, including the clinical disease, inheritance, prognosis and treatment, birth prevalence, and ethnic variability. The molecular basis of this disease is presented, including a discussion of the gene, mutations, and genotype/phenotype correlations. The models that have been used for delivering prenatal screening services in pilot trials are described, along with lessons learned, expected screening performance, and relevant ELSI considerations. A realistic view of laboratory issues is considered, including current standards of performance, guidelines and oversight, and quality assurance. Examples of current laboratory technologies for cystic fibrosis testing are displayed.

Original languageEnglish (US)
Pages (from-to)503-530
Number of pages28
JournalClinics in Laboratory Medicine
Volume23
Issue number2
StatePublished - Jun 2003
Externally publishedYes

Fingerprint

Prenatal Diagnosis
Cystic Fibrosis
Screening
Genetic Association Studies
Parturition
Guidelines
Technology
Quality assurance
Mutation
Genes
Testing

ASJC Scopus subject areas

  • Medicine(all)
  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Prenatal screening for cystic fibrosis. / Richards, Carolyn (Sue); Haddow, James E.

In: Clinics in Laboratory Medicine, Vol. 23, No. 2, 06.2003, p. 503-530.

Research output: Contribution to journalArticle

Richards, CS & Haddow, JE 2003, 'Prenatal screening for cystic fibrosis', Clinics in Laboratory Medicine, vol. 23, no. 2, pp. 503-530.
Richards, Carolyn (Sue) ; Haddow, James E. / Prenatal screening for cystic fibrosis. In: Clinics in Laboratory Medicine. 2003 ; Vol. 23, No. 2. pp. 503-530.
@article{01324b8f962e4110935f01098206b249,
title = "Prenatal screening for cystic fibrosis",
abstract = "This article focuses on essential components related to prenatal screening for cystic fibrosis, including the clinical disease, inheritance, prognosis and treatment, birth prevalence, and ethnic variability. The molecular basis of this disease is presented, including a discussion of the gene, mutations, and genotype/phenotype correlations. The models that have been used for delivering prenatal screening services in pilot trials are described, along with lessons learned, expected screening performance, and relevant ELSI considerations. A realistic view of laboratory issues is considered, including current standards of performance, guidelines and oversight, and quality assurance. Examples of current laboratory technologies for cystic fibrosis testing are displayed.",
author = "Richards, {Carolyn (Sue)} and Haddow, {James E.}",
year = "2003",
month = "6",
language = "English (US)",
volume = "23",
pages = "503--530",
journal = "Clinics in Laboratory Medicine",
issn = "0272-2712",
publisher = "W.B. Saunders Ltd",
number = "2",

}

TY - JOUR

T1 - Prenatal screening for cystic fibrosis

AU - Richards, Carolyn (Sue)

AU - Haddow, James E.

PY - 2003/6

Y1 - 2003/6

N2 - This article focuses on essential components related to prenatal screening for cystic fibrosis, including the clinical disease, inheritance, prognosis and treatment, birth prevalence, and ethnic variability. The molecular basis of this disease is presented, including a discussion of the gene, mutations, and genotype/phenotype correlations. The models that have been used for delivering prenatal screening services in pilot trials are described, along with lessons learned, expected screening performance, and relevant ELSI considerations. A realistic view of laboratory issues is considered, including current standards of performance, guidelines and oversight, and quality assurance. Examples of current laboratory technologies for cystic fibrosis testing are displayed.

AB - This article focuses on essential components related to prenatal screening for cystic fibrosis, including the clinical disease, inheritance, prognosis and treatment, birth prevalence, and ethnic variability. The molecular basis of this disease is presented, including a discussion of the gene, mutations, and genotype/phenotype correlations. The models that have been used for delivering prenatal screening services in pilot trials are described, along with lessons learned, expected screening performance, and relevant ELSI considerations. A realistic view of laboratory issues is considered, including current standards of performance, guidelines and oversight, and quality assurance. Examples of current laboratory technologies for cystic fibrosis testing are displayed.

UR - http://www.scopus.com/inward/record.url?scp=0038109959&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0038109959&partnerID=8YFLogxK

M3 - Article

VL - 23

SP - 503

EP - 530

JO - Clinics in Laboratory Medicine

JF - Clinics in Laboratory Medicine

SN - 0272-2712

IS - 2

ER -